Both AADR and ARKG are ETFs. Below is the comparison between AADR and ARKG.
| AADR | ARKG | |
|---|---|---|
| Security Type | ETF | ETF |
| Finny Score | 0 | 50 |
| Category | N/A | N/A |
| Family | AdvisorShares | ARK |
| Net Assets | $29.30M | $2.08B |
| Expense Ratio | N/A | N/A |
| Management Style | passive (index-based) | active |
| Dividend Yield | N/A | N/A |
| Underlying Index | -- | -- |
| YTD Return | N/A | N/A |
| 1-Year Return | N/A | N/A |
| 3-Year Return | N/A | N/A |
| 5-Year Return | N/A | N/A |
| 10-Year Return | N/A | N/A |
AADR
AADR description
AdvisorShares Trust - AdvisorShares Dorsey Wright ADR ETF is an exchange traded fund launched and managed by AdvisorShares Investments, LLC. It is co-managed by Dorsey, Wright & Associates, LLC. The fund invests in public equity markets of global region. It invests in stocks of companies operating across diversified sectors. The fund invests in momentum stocks of companies across diversified market capitalization. The fund seeks to benchmark the performance of its portfolio against the MSCI EAFE Index. AdvisorShares Trust - AdvisorShares Dorsey Wright ADR ETF was formed on July 20, 2010 and is domiciled in the United States.
AADR performance & returns
| YTD Return | N/A |
| 1-Month Return | N/A |
| 3-Month Return | N/A |
| 1-Year Return | N/A |
| 3-Year Return | N/A |
| 5-Year Return | N/A |
| 10-Year Return | N/A |
AADR holdings
Top 10 Holdings (34.61% of Total Assets)
| Name | Symbol | % Assets |
|---|---|---|
| Novo Nordisk A/S ADR | NVO | 5.32% |
| YPF SA ADR | YPF | 4.11% |
| ABB Ltd ADR | ABBNY | 3.60% |
| Mitsubishi UFJ Financial Group Inc ADR | MUFG | 3.24% |
| Pampa Energia SA ADR | PAM | 3.17% |
| UBS Group AG | UBSG | 3.15% |
| RELX PLC ADR | RELX | 3.02% |
| Cemex SAB de CV ADR | CX | 3.02% |
| POSCO Holdings Inc ADR | PKX | 3.01% |
| America Movil SAB de CV ADR - Series B | AMX | 2.99% |
AADR pros
None that we could think of.AADR cons
None that we could think of.Other relevant AADR comparisons
You may also want to check out the following AADR comparisons that investors often look for on Finny
ARKG
ARKG description
ARK ETF Trust - ARK Genomic Revolution ETF is an exchange traded fund launched and managed by ARK Investment Management LLC. It invests in public equity markets of global region. The fund invests in stocks of companies operating across diversified sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. The fund employs fundamental and quantitative analysis with bottom-up and top-down stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the NASDAQ Healthcare Index, the S&P 500 Index and the MSCI World Index. The fund employs internal and external research to create its portfolio. ARK ETF Trust - ARK Genomic Revolution ETF was formed on October 31, 2014 and is domiciled in the United States.
ARKG performance & returns
| YTD Return | N/A |
| 1-Month Return | N/A |
| 3-Month Return | N/A |
| 1-Year Return | N/A |
| 3-Year Return | N/A |
| 5-Year Return | N/A |
| 10-Year Return | N/A |
ARKG holdings
Top 10 Holdings (52.06% of Total Assets)
| Name | Symbol | % Assets |
|---|---|---|
| Exact Sciences Corp | EXAS | 10.43% |
| Schrodinger Inc Ordinary Shares | SDGR | 7.37% |
| Pacific Biosciences of California Inc | PACB | 6.00% |
| Ginkgo Bioworks Holdings Inc | DNA | 5.11% |
| Teladoc Health Inc | TDOC | 4.84% |
| Ionis Pharmaceuticals Inc | IONS | 4.16% |
| Adaptive Biotechnologies Corp | ADPT | 3.74% |
| Accolade Inc Ordinary Shares | ACCD | 3.58% |
| CRISPR Therapeutics AG | CRSP | 3.54% |
| Intellia Therapeutics Inc | NTLA | 3.28% |
ARKG pros
The following are ARKG strengths from our perspective:
- ARKG 3-year return is 34.54%, which is higher than the 3-year return of the benchmark index (MSCI ACWI NR USD), 8.21%.
- ARKG 5-year return is 24.54%, which is higher than the 5-year return of the benchmark index (MSCI ACWI NR USD), 10.45%.
ARKG cons
The following are ARKG weaknesses from our perspective:
- ARKG net assets are $886.97 million. This fund is not a popular choice with retail investors.
- ARKG expense ratio is 0.75%, which is not negligible. Is the fund expensive to you, and does it align to your investment strategy?
Other relevant ARKG comparisons
You may also want to check out the following ARKG comparisons that investors often look for on Finny